Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R de Groot

Showing results (561-570 of 568) with videos related to

Pageof 57
Sort By:
You have reached the last page of results.This site can display upto 568 results.
BMJ Open|August 27, 2020
Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillationGordon Chu, Jaap Seelig, Emmy M Trinks-Roerdink, et al.
The New England Journal of Medicine|January 5, 2022
Eltrombopag Added to Immunosuppression in Severe Aplastic AnemiaRégis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli, et al.
Circulation|April 25, 2025
Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL TrialLouise R A Olde Nordkamp, Jolien A de Veld, Abdul Ghani, et al.
Thrombosis Research|November 15, 2025
Predicting clinically relevant bleeding in new-onset atrial fibrillation patients initiating oral anticoagulant therapy: External validation of the AF-BLEED scoreS F B van der Horst, G Chu, J Seelig, et al.
Circulation|November 15, 2021
Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN TrialReinoud E Knops, Willeke van der Stuijt, Peter Paul H M Delnoy, et al.
Circulation. Cardiovascular Quality and Outcomes|November 19, 2024
Quality of Life in Subcutaneous or Transvenous Implantable Cardioverter-Defibrillator Patients: A Secondary Analysis of the PRAETORIAN TrialReinoud E Knops, Jolien A de Veld, Abdul Ghani, et al.
Circulation. Arrhythmia and Electrophysiology|December 3, 2024
Inappropriate Therapy and Shock Rates Between the Subcutaneous and Transvenous Implantable Cardiac Defibrillator: A Secondary Analysis of the PRAETORIAN TrialLouise R A Olde Nordkamp, Shari Pepplinkhuizen, Abdul Ghani, et al.
European Heart Journal|August 28, 2022
Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trialReinoud E Knops, Shari Pepplinkhuizen, Peter Paul H M Delnoy, et al.
Pageof 57

Showing results (561-570 of 568) with videos related to

Sort By:
Pageof 57
You have reached the last page of results.This site can display upto 568 results.
BMJ Open|August 27, 2020
Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillationGordon Chu, Jaap Seelig, Emmy M Trinks-Roerdink, et al.
The New England Journal of Medicine|January 5, 2022
Eltrombopag Added to Immunosuppression in Severe Aplastic AnemiaRégis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli, et al.
Circulation|April 25, 2025
Device-related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-term Follow-up: the PRAETORIAN-XL TrialLouise R A Olde Nordkamp, Jolien A de Veld, Abdul Ghani, et al.
Thrombosis Research|November 15, 2025
Predicting clinically relevant bleeding in new-onset atrial fibrillation patients initiating oral anticoagulant therapy: External validation of the AF-BLEED scoreS F B van der Horst, G Chu, J Seelig, et al.
Circulation|November 15, 2021
Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN TrialReinoud E Knops, Willeke van der Stuijt, Peter Paul H M Delnoy, et al.
Circulation. Cardiovascular Quality and Outcomes|November 19, 2024
Quality of Life in Subcutaneous or Transvenous Implantable Cardioverter-Defibrillator Patients: A Secondary Analysis of the PRAETORIAN TrialReinoud E Knops, Jolien A de Veld, Abdul Ghani, et al.
Circulation. Arrhythmia and Electrophysiology|December 3, 2024
Inappropriate Therapy and Shock Rates Between the Subcutaneous and Transvenous Implantable Cardiac Defibrillator: A Secondary Analysis of the PRAETORIAN TrialLouise R A Olde Nordkamp, Shari Pepplinkhuizen, Abdul Ghani, et al.
European Heart Journal|August 28, 2022
Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trialReinoud E Knops, Shari Pepplinkhuizen, Peter Paul H M Delnoy, et al.
Pageof 57